The company will use the funding to scale its commercial reach, expand operational capabilities and strategic partnerships, and focus on R&D
Cleerly has raised $43m in Series B financing round, and has unveiled its digital care pathway solution for the prevention of heart attack.
The Series B round which brings the total investment to $54m was led by Vensana Capital.
LRVHealth, New Leaf Venture Partners, DigiTx Partners, the American College of Cardiology, Cigna Ventures have participated in the funding round, along with the existing investors.
The company intends to use the Series B funding to scale its commercial reach, expand operational capabilities and strategic partnerships, and focus on research and development.
As part of the funding, Justin Klein from Vensana Capital, Tripp Peake from LRVHealth and Vijay Lathi from New Leaf Venture Partners will be appointed as Cleerly’s Board of Directors.
Vensana Capital managing partner Justin Klein said: “We see Cleerly as the future of how coronary artery disease will be evaluated, and we support the company’s mission to tailor a personalised approach to diagnosis, management and treatment, and to validate all of this with world-class clinical evidence of utility and cost-effectiveness.
“With Cleerly’s industry-leading technology platform and inherent value propositions, we believe Cleerly is ideally positioned to inform a new standard of care for how we manage coronary artery disease at scale.”
Cleerly was founded based on more than a decade of foundational research to develop advanced artificial intelligence (AI) and machine learning algorithms.
Research at the Dalio Institute for Cardiovascular Imaging at the New York-Presbyterian Hospital and Weill Cornell Medicine supported Cleerly in developing its technologies.
It comprised large-scale clinical trials with more than 50,000 patients, to study how imaging can be used to better understand heart disease and project patient outcomes.
Cleerly leverages non-invasive coronary computed tomography (CT) angiography to perform comprehensive coronary artery phenotyping through AI-enabled and FDA-cleared solutions.
The technology leveraged millions of annotated lab images to build more than two dozen algorithms for quantifying and characterising the type of coronary artery disease and other cardiovascular disorders.
Beyond end-to-end AI for deep coronary phenotyping, Cleerly offers tools for clinicians, along with interactive and personalised, patient-facing tools.
Cleerly founder and CEO James Min said: “Advanced imaging has been key to diagnosing and preventing the most common causes of cancer for years, but we’re not using it yet to prevent the most common cause of death.
“We use 3D mammograms, colonoscopies and lung CT scans to find and prevent breast, colon and lung cancer, but we haven’t had similar capabilities for the world’s number one killer – heart disease.
“Through the application of artificial intelligence that is constantly being refined with our unprecedented volume of accruing and exclusive clinical data, Cleerly is finally bringing heart disease diagnosis and prevention into the twenty-first century.”